Sophie Marolleau
YOU?
Author Swipe
View article: Model-driven scheduling of a novel anti-cancer polymer prodrug administered subcutaneously
Model-driven scheduling of a novel anti-cancer polymer prodrug administered subcutaneously Open
Paclitaxel (Ptx) is a key chemotherapeutic, but its commercial formulations cause toxicity due to emulsifiers. New Ptx formulations aim to improve efficacy and pharmacokinetics (PK), but are exclusively devoted to intravenous administratio…
View article: Model-Driven Scheduling of Nanocarriers: Application to an Anticancer Polymer Prodrug Administered Subcutaneously
Model-Driven Scheduling of Nanocarriers: Application to an Anticancer Polymer Prodrug Administered Subcutaneously Open
Paclitaxel (Ptx) is a key chemotherapeutic, but its commercial formulations cause toxicity due to emulsifiers. New Ptx formulations aim to improve efficacy and pharmacokinetics (PK), but are exclusively devoted to intravenous administratio…
View article: 1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial Open
View article: Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money?
Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money? Open
3085 Background: Immune checkpoint inhibitors are given as fixed doses, which may lead to drug exposure exceeding the plasma concentrations required for target engagement. If confirmed, this could pave the way for de-escalating treatments …
View article: Abstract 7162: Killing a fly with a sledgehammer: standard flat-dosing administration of Atezolizumab leads to marked overexposure in real-world lung cancer patients
Abstract 7162: Killing a fly with a sledgehammer: standard flat-dosing administration of Atezolizumab leads to marked overexposure in real-world lung cancer patients Open
Atezolizumab is an anti-PDL1 approved for treating small cell lung cancer and non-small cell lung cancers. A threshold of 6 µg/ml in plasma has been associated with target engagement with Atezolizumab. The extent to which patients could be…
View article: Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients
Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients Open
Atezolizumab is an anti‐PDL1 approved for treating lung cancer. A threshold of 6 μg/mL in plasma has been associated with target engagement. The extent to which patients could be overexposed with the standard 1200 mg q3w dosing remains unk…
View article: Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?
Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model? Open
International audience